Tysabri Európai Unió - magyar - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Zinbryta Európai Unió - magyar - EMA (European Medicines Agency)

zinbryta

biogen idec ltd - daklizumab - szklerózis multiplex - immunszuppresszánsok - a zinbryta felnőtt betegeknél a sclerosis multiplex (rms) relapszáló formái,.

Spinraza Európai Unió - magyar - EMA (European Medicines Agency)

spinraza

biogen netherlands b.v. - nusinersen nátrium - izomsorvadás, spinal - egyéb idegrendszeri gyógyszerek - a spinraza az 5q spinalis izomsorvadás kezelésére javallt.

Vumerity Európai Unió - magyar - EMA (European Medicines Agency)

vumerity

biogen netherlands b.v. - diroximel fumarate (biib098) - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).